Cynata Therapeutics Limited (CYYNF)
USD 0.19
(0.0%)
USD 0.19
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 | 8.38 Million AUD | -55.84% |
| 2023 | 18.99 Million AUD | -28.46% |
| 2022 | 26.54 Million AUD | -11.43% |
| 2021 | 29.97 Million AUD | 71.47% |
| 2020 | 17.48 Million AUD | 42.7% |
| 2019 | 12.24 Million AUD | -24.07% |
| 2018 | 16.13 Million AUD | 13.18% |
| 2017 | 14.25 Million AUD | 57.84% |
| 2016 | 9.03 Million AUD | -1.04% |
| 2015 | 9.12 Million AUD | -8.07% |
| 2014 | 9.92 Million AUD | 453.73% |
| 2013 | 1.79 Million AUD | 76.29% |
| 2012 | 1.01 Million AUD | -16.51% |
| 2011 | 1.21 Million AUD | -2.48% |
| 2010 | 1.24 Million AUD | -12.07% |
| 2009 | 1.42 Million AUD | -38.98% |
| 2008 | 2.32 Million AUD | -34.56% |
| 2007 | 3.55 Million AUD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q4 | 8.38 Million AUD | 0.0% |
| 2024 FY | 8.38 Million AUD | -55.84% |
| 2024 Q2 | 13.45 Million AUD | 0.0% |
| 2024 Q1 | 13.45 Million AUD | -49.33% |
| 2023 Q2 | 20.52 Million AUD | 0.0% |
| 2023 Q3 | 18.99 Million AUD | -7.45% |
| 2023 FY | 18.99 Million AUD | -28.46% |
| 2023 Q4 | 26.54 Million AUD | 39.77% |
| 2023 Q1 | 20.52 Million AUD | -22.69% |
| 2022 Q1 | 29.53 Million AUD | -1.48% |
| 2022 Q2 | 29.53 Million AUD | 0.0% |
| 2022 Q3 | 26.54 Million AUD | -10.11% |
| 2022 FY | 26.54 Million AUD | -11.43% |
| 2022 Q4 | 26.54 Million AUD | 0.0% |
| 2021 Q2 | 28.1 Million AUD | 0.0% |
| 2021 FY | 29.97 Million AUD | 71.47% |
| 2021 Q3 | 29.97 Million AUD | 6.67% |
| 2021 Q4 | 29.97 Million AUD | 0.0% |
| 2021 Q1 | 28.1 Million AUD | 60.75% |
| 2020 FY | 17.48 Million AUD | 42.7% |
| 2020 Q1 | 10.82 Million AUD | -11.59% |
| 2020 Q2 | 10.82 Million AUD | 0.0% |
| 2020 Q4 | 17.48 Million AUD | 0.0% |
| 2020 Q3 | 17.48 Million AUD | 61.42% |
| 2019 Q2 | 15.88 Million AUD | 0.0% |
| 2019 Q1 | 15.88 Million AUD | -1.57% |
| 2019 Q3 | 12.24 Million AUD | -22.86% |
| 2019 FY | 12.24 Million AUD | -24.07% |
| 2019 Q4 | 12.24 Million AUD | 0.0% |
| 2018 Q4 | 16.13 Million AUD | 0.0% |
| 2018 FY | 16.13 Million AUD | 13.18% |
| 2018 Q3 | 16.13 Million AUD | 28.19% |
| 2018 Q2 | 12.58 Million AUD | 0.0% |
| 2018 Q1 | 12.58 Million AUD | -11.71% |
| 2017 Q2 | 7.9 Million AUD | 0.0% |
| 2017 FY | 14.25 Million AUD | 57.84% |
| 2017 Q4 | 14.25 Million AUD | 0.0% |
| 2017 Q3 | 14.25 Million AUD | 80.4% |
| 2017 Q1 | 7.9 Million AUD | -12.5% |
| 2016 Q1 | 11.58 Million AUD | 27.01% |
| 2016 Q3 | 9.03 Million AUD | -22.08% |
| 2016 Q2 | 11.58 Million AUD | 0.0% |
| 2016 FY | 9.03 Million AUD | -1.04% |
| 2016 Q4 | 9.03 Million AUD | 0.0% |
| 2015 FY | 9.12 Million AUD | -8.07% |
| 2015 Q4 | 9.12 Million AUD | 0.0% |
| 2015 Q3 | 9.12 Million AUD | -17.2% |
| 2015 Q1 | 11.02 Million AUD | 11.04% |
| 2015 Q2 | 11.02 Million AUD | 0.0% |
| 2014 FY | 9.92 Million AUD | 453.73% |
| 2014 Q4 | 9.92 Million AUD | 0.0% |
| 2014 Q3 | 9.92 Million AUD | -10.53% |
| 2014 Q2 | 11.09 Million AUD | 0.0% |
| 2014 Q1 | 11.09 Million AUD | 518.93% |
| 2013 Q4 | 1.79 Million AUD | 0.0% |
| 2013 Q3 | 1.79 Million AUD | 0.0% |
| 2013 FY | 1.79 Million AUD | 76.29% |
| 2012 Q4 | 1.01 Million AUD | 0.0% |
| 2012 FY | 1.01 Million AUD | -16.51% |
| 2011 Q4 | 1.21 Million AUD | 0.0% |
| 2011 FY | 1.21 Million AUD | -2.48% |
| 2010 Q4 | 1.24 Million AUD | 0.0% |
| 2010 FY | 1.24 Million AUD | -12.07% |
| 2009 FY | 1.42 Million AUD | -38.98% |
| 2009 Q4 | 1.42 Million AUD | 0.0% |
| 2008 FY | 2.32 Million AUD | -34.56% |
| 2008 Q4 | 2.32 Million AUD | 0.0% |
| 2007 FY | 3.55 Million AUD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 78.407% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -16.185% |
| SQZ Biotechnologies Company | 107.18 Million USD | 92.174% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 20.52% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 93.558% |
| Mesoblast Limited | 667.9 Million USD | 98.744% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -11491.64% |
| Genus plc | 1.02 Billion USD | 99.185% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -517.534% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -1580.889% |
| Marizyme, Inc. | 22.01 Million USD | 61.898% |
| ContraFect Corporation | 20.67 Million USD | 59.436% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -1237.845% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -2048.827% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -2094.87% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -485.761% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -102.321% |
| MultiCell Technologies, Inc. | 126.22 USD | -6645669.292% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -792.667% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 93.473% |
| EV Biologics, Inc. | 431.71 Thousand USD | -1843.02% |
| Q BioMed Inc. | 3.51 Million USD | -138.608% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 76.155% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -988.478% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -3110.497% |
| Biomind Labs Inc. | 73.81 Thousand USD | -11263.321% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 462.85 Million USD | 98.188% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 72.053% |
| Skye Bioscience, Inc. | 11.94 Million USD | 29.749% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -153.192% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -205.436% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -328.37% |
| IMV Inc. | 31.33 Million USD | 73.229% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -1120.14% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -222.23% |
| GB Sciences, Inc. | 103.44 Thousand USD | -8009.172% |
| Alpha Cognition Inc. | 2.45 Million USD | -242.076% |
| HST Global, Inc. | 1526.00 USD | -549591.35% |
| CSL Limited | 38.02 Billion USD | 99.978% |
| Halberd Corporation | 10.13 Thousand USD | -82698.243% |
| Enzolytics Inc. | 361.7 Million USD | 97.681% |
| Resverlogix Corp. | 8.11 Million USD | -3.368% |
| Affymax, Inc. | 7.44 Million USD | -12.7% |
| SYBLEU INC | 330.46 Thousand USD | -2438.306% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -346.689% |
| argenx SE | 4.54 Billion USD | 99.815% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 69.982% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 82.415% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -36721.43% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 6.267% |
| AVAX Technologies, Inc. | 7.37 Million USD | -13.706% |
| Zenith Capital Corp. | 7410.00 USD | -113102.294% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.752% |
| Ember Therapeutics, Inc. | 184.00 USD | -4558753.261% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -2506.629% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -3109.428% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 98.121% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -478.965% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 3.02 Million USD | -177.291% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 84.083% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -803.949% |
| BioStem Technologies, Inc. | 14.56 Million USD | 42.389% |
| ONE Bio Corp. | 70.08 Million USD | 88.031% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -14592.069% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -363029.437% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -749.046% |
| Agentix Corp. | 261.39 Thousand USD | -3109.084% |
| LadRx Corporation | 2.3 Million USD | -263.463% |
| Cell Source, Inc. | 195.17 Thousand USD | -4197.918% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -1645.535% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -2272.14% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -2272.14% |
| NovAccess Global Inc. | 62.24 Thousand USD | -13375.598% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -1211.375% |
| Itoco Inc. | 1.4 Million USD | -499.133% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -8669.133% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -7813.481% |
| Kadimastem Ltd | 2.3 Million USD | -264.062% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -10886.052% |
| CytoDyn Inc. | 11.13 Million USD | 24.674% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -5767.086% |
| Mobile Lads Corp. | 52.00 USD | -16131226.923% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -46814.374% |
| Qrons Inc. | 420.00 USD | -1997111.905% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -2076.114% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -1419.287% |
| Rebus Holdings, Inc. | 5000.00 USD | -167665.8% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -1948.813% |
| International Stem Cell Corporation | 5.39 Million USD | -55.627% |
| Bioxytran, Inc. | 137.63 Thousand USD | -5994.458% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 44.085% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 49.404% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -10518.089% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -870.107% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -11.591% |
| Neutra Corp. | 2851.00 USD | -294122.729% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 74.115% |
| PureTech Health plc | 693.97 Million USD | 98.791% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -3.93% |
| IXICO plc | 15.84 Million USD | 47.057% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -1.283% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 91.882% |
| CSL Limited | 38.02 Billion USD | 99.978% |
| Cellectis S.A. | 333.99 Million USD | 97.488% |